327 related articles for article (PubMed ID: 37999893)
1. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic LM; Liu K; VanDyke D; Fabilane CS; Spangler JB
BioDrugs; 2024 Mar; 38(2):227-248. PubMed ID: 37999893
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y; Kolios AGA; Liu Y; Zhang B; Li H; Tsokos GC; Zhang X
Trends Mol Med; 2022 Jul; 28(7):596-612. PubMed ID: 35624009
[TBL] [Abstract][Full Text] [Related]
3. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
VanDyke D; Iglesias M; Tomala J; Young A; Smith J; Perry JA; Gebara E; Cross AR; Cheung LS; Dykema AG; Orcutt-Jahns BT; Henclová T; Golias J; Balolong J; Tomasovic LM; Funda D; Meyer AS; Pardoll DM; Hester J; Issa F; Hunter CA; Anderson MS; Bluestone JA; Raimondi G; Spangler JB
Cell Rep; 2022 Oct; 41(3):111478. PubMed ID: 36261022
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases.
Jin D; Jiang Y; Chang L; Wei J; Sun J
Int Immunopharmacol; 2022 Sep; 110():108935. PubMed ID: 35732097
[TBL] [Abstract][Full Text] [Related]
5. IL-2-based approaches to Treg enhancement.
Harris F; Berdugo YA; Tree T
Clin Exp Immunol; 2023 Mar; 211(2):149-163. PubMed ID: 36399073
[TBL] [Abstract][Full Text] [Related]
6. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity.
Zhou P
Cytokine Growth Factor Rev; 2022 Oct; 67():80-88. PubMed ID: 35803833
[TBL] [Abstract][Full Text] [Related]
7. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
8. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
Kosmaczewska A
Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.
Tahvildari M; Dana R
J Immunol; 2019 Dec; 203(11):2749-2755. PubMed ID: 31740549
[TBL] [Abstract][Full Text] [Related]
10. The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.
Papillion A; Ballesteros-Tato A
Front Immunol; 2021; 12():667342. PubMed ID: 33986755
[TBL] [Abstract][Full Text] [Related]
11. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
12. Strategies to therapeutically modulate cytokine action.
Leonard WJ; Lin JX
Nat Rev Drug Discov; 2023 Oct; 22(10):827-854. PubMed ID: 37542128
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
14. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.
Spangler JB; Trotta E; Tomala J; Peck A; Young TA; Savvides CS; Silveria S; Votavova P; Salafsky J; Pande VS; Kovar M; Bluestone JA; Garcia KC
J Immunol; 2018 Oct; 201(7):2094-2106. PubMed ID: 30104245
[TBL] [Abstract][Full Text] [Related]
15. Engineering IL-2 to Give New Life to T Cell Immunotherapy.
Overwijk WW; Tagliaferri MA; Zalevsky J
Annu Rev Med; 2021 Jan; 72():281-311. PubMed ID: 33158368
[TBL] [Abstract][Full Text] [Related]
16. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
17. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
18. An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases.
Radi H; Ferdosi-Shahandashti E; Kardar GA; Hafezi N
J Interferon Cytokine Res; 2024 Apr; 44(4):143-157. PubMed ID: 38421721
[TBL] [Abstract][Full Text] [Related]
19. Natural and modified IL-2 for the treatment of cancer and autoimmune diseases.
Mizui M
Clin Immunol; 2019 Sep; 206():63-70. PubMed ID: 30415086
[TBL] [Abstract][Full Text] [Related]
20. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
Wang H; Borlongan M; Hemminki A; Basnet S; Sah N; Kaufman HL; Rabkin SD; Saha D
Hum Gene Ther; 2023 Sep; 34(17-18):878-895. PubMed ID: 37578106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
